Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease
BackgroundProgramed death-ligand 1 (PD-L1) is overexpressed on renal tubular and vascular epithelial cells in inflammatory kidney diseases as well as on aged kidney podocytes, contributing to chronic kidney disease (CKD) progression. The association of serum soluble programed death-ligand 1 (sPD-L1)...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1530804/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576057647038464 |
|---|---|
| author | Ayaka Hayashi Ayaka Hayashi Hiroto Ishihara Mayuko Kawabe Kazuhiko Kato Kazuhiko Kato Akio Nakashima Akio Nakashima Izumi Yamamoto Teppei Sakano Teppei Sakano Hiroe Kobashi Makoto Morita Makoto Morita Takashi Yokoo Mitsuyoshi Urashima |
| author_facet | Ayaka Hayashi Ayaka Hayashi Hiroto Ishihara Mayuko Kawabe Kazuhiko Kato Kazuhiko Kato Akio Nakashima Akio Nakashima Izumi Yamamoto Teppei Sakano Teppei Sakano Hiroe Kobashi Makoto Morita Makoto Morita Takashi Yokoo Mitsuyoshi Urashima |
| author_sort | Ayaka Hayashi |
| collection | DOAJ |
| description | BackgroundProgramed death-ligand 1 (PD-L1) is overexpressed on renal tubular and vascular epithelial cells in inflammatory kidney diseases as well as on aged kidney podocytes, contributing to chronic kidney disease (CKD) progression. The association of serum soluble programed death-ligand 1 (sPD-L1) levels and chronic kidney disease (CKD) progression is unknown.MethodsTo compare serum sPD-L1 levels among healthy individuals and patients with various CKD stages, including those undergoing dialysis, a secondary analysis was performed using clinical data and residual serum samples from four distinct cohorts, each prospectively collected for different research purposes: The Vaccine Cohort (2021–2022), the Cancer Cohort (2010–2018), the Dialysis Initiation Cohort (2023–2024), and the Dialysis Maintenance Cohort (2011–2015) included patients on stable maintenance dialysis.ResultsThe study analyzed serum sPD-L1 levels in 2,829 participants (mean age, 54.2 years; male, 54.2%) across the four cohorts. In the Vaccine and Cancer cohorts, sPD-L1 levels increased significantly with age (P < 0.001) and male sex (P < 0.001). In the Vaccine Cohort, elevated median sPD-L1 levels (pg/mL) were significantly associated with CKD stage progression (P < 0.001), showing exponentially higher levels with CKD progression. A similar association was observed and validated in the Cancer Cohort (P < 0.001). In the Dialysis Initiation Cohort (n = 15), sPD-L1 levels significantly increased three months after dialysis initiation compared to pre-dialysis levels (P = 0.03). In the Dialysis Maintenance Cohort, sPD-L1 levels increased with longer dialysis duration (P < 0.001).ConclusionSerum sPD-L1 levels might increase with CKD stage progression, dialysis initiation and longer dialysis duration. Further clinical investigation is required to confirm these results. |
| format | Article |
| id | doaj-art-8787698d8ab04c30977ea9859f4a11ce |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-8787698d8ab04c30977ea9859f4a11ce2025-01-31T13:30:13ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011210.3389/fmed.2025.15308041530804Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney diseaseAyaka Hayashi0Ayaka Hayashi1Hiroto Ishihara2Mayuko Kawabe3Kazuhiko Kato4Kazuhiko Kato5Akio Nakashima6Akio Nakashima7Izumi Yamamoto8Teppei Sakano9Teppei Sakano10Hiroe Kobashi11Makoto Morita12Makoto Morita13Takashi Yokoo14Mitsuyoshi Urashima15Division of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Innovation for Medical Information Technology, The Jikei University School of Medicine, Tokyo, JapanAllm, Inc., Tokyo, JapanDepartment of Infectious Disease, Team Medical Clinic, Tokyo, JapanDivision of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo, JapanPfizer Japan Inc., Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo, JapanBackgroundProgramed death-ligand 1 (PD-L1) is overexpressed on renal tubular and vascular epithelial cells in inflammatory kidney diseases as well as on aged kidney podocytes, contributing to chronic kidney disease (CKD) progression. The association of serum soluble programed death-ligand 1 (sPD-L1) levels and chronic kidney disease (CKD) progression is unknown.MethodsTo compare serum sPD-L1 levels among healthy individuals and patients with various CKD stages, including those undergoing dialysis, a secondary analysis was performed using clinical data and residual serum samples from four distinct cohorts, each prospectively collected for different research purposes: The Vaccine Cohort (2021–2022), the Cancer Cohort (2010–2018), the Dialysis Initiation Cohort (2023–2024), and the Dialysis Maintenance Cohort (2011–2015) included patients on stable maintenance dialysis.ResultsThe study analyzed serum sPD-L1 levels in 2,829 participants (mean age, 54.2 years; male, 54.2%) across the four cohorts. In the Vaccine and Cancer cohorts, sPD-L1 levels increased significantly with age (P < 0.001) and male sex (P < 0.001). In the Vaccine Cohort, elevated median sPD-L1 levels (pg/mL) were significantly associated with CKD stage progression (P < 0.001), showing exponentially higher levels with CKD progression. A similar association was observed and validated in the Cancer Cohort (P < 0.001). In the Dialysis Initiation Cohort (n = 15), sPD-L1 levels significantly increased three months after dialysis initiation compared to pre-dialysis levels (P = 0.03). In the Dialysis Maintenance Cohort, sPD-L1 levels increased with longer dialysis duration (P < 0.001).ConclusionSerum sPD-L1 levels might increase with CKD stage progression, dialysis initiation and longer dialysis duration. Further clinical investigation is required to confirm these results.https://www.frontiersin.org/articles/10.3389/fmed.2025.1530804/fullPD-1PD-L1chronic kidney diseasedialysisimmune checkpoint inhibitorsoluble PD-L1 (sPD-L1) |
| spellingShingle | Ayaka Hayashi Ayaka Hayashi Hiroto Ishihara Mayuko Kawabe Kazuhiko Kato Kazuhiko Kato Akio Nakashima Akio Nakashima Izumi Yamamoto Teppei Sakano Teppei Sakano Hiroe Kobashi Makoto Morita Makoto Morita Takashi Yokoo Mitsuyoshi Urashima Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease Frontiers in Medicine PD-1 PD-L1 chronic kidney disease dialysis immune checkpoint inhibitor soluble PD-L1 (sPD-L1) |
| title | Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease |
| title_full | Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease |
| title_fullStr | Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease |
| title_full_unstemmed | Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease |
| title_short | Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease |
| title_sort | increased serum soluble pd l1 levels in patients with advanced stages of chronic kidney disease |
| topic | PD-1 PD-L1 chronic kidney disease dialysis immune checkpoint inhibitor soluble PD-L1 (sPD-L1) |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1530804/full |
| work_keys_str_mv | AT ayakahayashi increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT ayakahayashi increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT hirotoishihara increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT mayukokawabe increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT kazuhikokato increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT kazuhikokato increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT akionakashima increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT akionakashima increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT izumiyamamoto increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT teppeisakano increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT teppeisakano increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT hiroekobashi increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT makotomorita increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT makotomorita increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT takashiyokoo increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease AT mitsuyoshiurashima increasedserumsolublepdl1levelsinpatientswithadvancedstagesofchronickidneydisease |